University of Kentucky
Lexington, Kentucky, 40507, United States
NCT Number: NCT05019430
Cocaine potently inhibits the reuptake of serotonin (5-HT). Increased synaptic 5-HT resulting from this reuptake inhibition activates multiple 5-HT receptor subtypes. Some of these receptor subtypes have been implicated in the abuse-related effects of cocaine, including its primary reinforcing effects (i.e., cocaine taking behavior). 5-HT1b receptors, which are autoreceptors on 5-HT nerve endings that regulate 5-HT release and heteroreceptors that also mediate other neurotransmitter release, play a particularly important role in cocaine effects, likely because they are highly expressed in the mesocorticolimbic system. The 5-HT1b system displays profound dysregulation during both active cocaine use and abstinence. Initial preclinical research showed that selective 5-HT1b agonists enhanced the reinforcing and locomotor effects of cocaine during ongoing cocaine administration, but subsequent research showed that these agents robustly attenuated reinstatement of cocaine- and cue-primed cocaine seeking behavior. These findings have been replicated in rigorously conducted studies using multiple schedules of reinforcement and negative sucrose reinforcement controls across laboratories. Notably, though, these preclinical studies used compounds not approved for use in humans, hindering translation. Recently published data show that zolmitriptan, a commercially available selective 5-HT1b agonist migraine medication, also selectively attenuates the reinforcing and other abuse-related effects of cocaine, regardless of stage of use (i.e., ongoing or extinguished cocaine self-administration).
Although a robust preclinical literature supports the premise that 5-HT1b activation reduces a number of cocaine-associated behaviors (e.g., self-administration, cocaine seeking), this area remains unstudied in humans. The overarching goal of this project is to advance these promising preclinical findings, specifically those with zolmitriptan, to a clinical population, thereby demonstrating that the 5-HT1b system plays a key role in the effects of cocaine in humans
Looking for future studies?
Notify Me18 year–55 year
All sexes
Interventional
Early Phase 1
Lexington, Kentucky, 40507, United States
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
The pharmacodynamic effects of cocaine will be determined during maintenance on placebo and zolmitriptan.
The pharmacodynamic effects of placebo will be determined.
The pharmacodynamic effects of zolmitriptan maintenance will be determined.
Time frame: Over approximately four hours on each experimental session day, which generally occurred on Days 5-7, 13-15, 21-23 and 29-31 of inpatient admission.
Number of Times Subjects Choose Cocaine (Maximum of 5 Choices) Over Money
William Stoops
Other
Behavioral Effects of Drugs (Inpatient): 42 (Cocaine and Zolmitriptan)
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT05857852
Chemically-Induced Disorders, Cocaine Abuse
Charlottesville, Virginia, United States
View Trial DetailsNCT05610072
Chemically-Induced Disorders, Cocaine Use Disorder
Lexington, Kentucky, United States
View Trial DetailsNCT06343532
Cocaine Use Disorder
Overland Park, Kansas, United States
View Trial DetailsNCT06273540
Cocaine Use Disorder
Overland Park, Kansas, United States
View Trial Details